Table 5.

Regression of percent change in HtTKV versus change in urine biomarkers by study group (placebo and pravastatin)

VariableGroupModelEstimate ± SEM95% Confidence LimitsP Value
Citrate, mmol/mmol creatininePlaceboUnadjusted−0.007±0.004−0.02 to 0.0010.09
Model 1−0.008±0.004−0.02 to −0.0040.04
Model 2−0.008±0.004−0.02 to −0.0030.04
PGF2α, µg/mmol creatininePlaceboUnadjusted−0.007±0.003−0.01 to −0.0010.03
Model 1−0.006±0.003−0.01 to −0.0010.03
Model 2−0.006±0.003−0.01 to −0.0010.03
8-HETE, µg/mmol creatininePravastatinUnadjusted0.14±0.060.01 to 0.270.03
Model 10.17±0.060.05 to 0.290.01
Model 20.18±0.060.06 to 0.300.01
9-HETE, µg/mmol creatinine PravastatinUnadjusted0.15±0.070.01 to 0.290.03
Model 10.22±0.060.09 to 0.350.001
Model 20.23±0.060.11 to 0.36<0.001
11-HETE, µg/mmol creatinine PravastatinUnadjusted0.18±0.11−0.05 to 0.400.11
Model 10.23±0.100.01 to 0.440.04
Model 20.26±0.100.04 to 0.470.02
  • Results are presented as the estimate±SEM with 95% confidence limits. Regression models included the following: model 1, adjusted for age and sex; and model 2, adjusted for age, sex, log-transformed GFR, and systolic BP. HtTKV, height-corrected total kidney volume; HETE, hydroxyeicosatetraenoic acid.